Echinocandins: A new class of antifungal agents, a new mechanism of action;Les échinocandines: Une nouvelle classe thérapeutique antifongique, un nouveau mécanisme d'action

Journal de Mycologie Medicale

Volumn 12, Issue 3 SUPPL., 2002, Pages

  Datry, A ^a   Thellier, M ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

(1 3) D glucane synthase; Caspofungin; Echinocandins; Mode of action

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN B; FLUCONAZOLE;

ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; FEVER; FUNGICIDAL ACTIVITY; HUMAN; MYCOSIS; NAUSEA; VOMITING;

EID: 0036742636     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Abruzzo GK, Gill CJ, Flattery AM et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 1997;41:2333-8.
2. Abruzzo GK, Flattery AM, Gill CJ et al. Evaluation of the echinocandin antifungal MK-0991 (L-743, 872): efficacies of mouses models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob Agents Chemother 2000;44:2310-8.
3. Annaissie E. Opportunistic mycoses in the immunocompromised host: experienced at a cancer center and review. Clin Infect Dis 1992;14:S43-S53.
4. th ICAAC;2000 Sept 18;Toronto.
5. Balani SK, Xu X, Arison BH et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000;28:1274-8.
6. Bartizal K, Gill CJ, Abruzzo CK et al. In vitro preclinical evaluation of studies with the echinocandin antifungal MK-0991(L743, 872). Antimicrob Agents Chemother 1997;2326-32.
7. Beck-Sagué C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, to National Nosocomial Infections Surveillance System. J Infect Dis 1991;167:1247-51.
8. th ICAAC;1996 Sep 15; New Orleans.
9. Caspofungin: L743,872, MK-0991, MK-991. Drugs R-D 1999;1:165-7.
10. Datry A, Thellier M, Alfa Cisse O, Danis M. Utilisation des antifongiques dans le traitement des candidoses systémiques: antifongigramme, point sur les résistances, données pharmacologiques. Ann Fr Anesth Réanim 2001;20:389-93.
11. Denning DW. Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. J Microb Chemother 1997;40:611-4.
12. Edmond MB, Wallace SE, McClish DK et al. Nosocomial blood-streams infections in United States hospitals: a three years analysis. Clin Infect Dis 1999;29:239-44.
13. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-6.
14. th ICAAC;1998 Sep 25; San Diego.
15. th ICAAC; 2000 Sep 18;Toronto.
16. Franzot SP, Casadevall A. Pneumocandin L-743, 872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 1997;41:331-6.
17. Graybill JR, Najvar LK, Montalbo EM et al. Treatment of histoplasmosis with MK 0991 (L-743, 872). Antimicrob Agents Chemother 1998;42:151-3.
18. Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin N Am 1995;9:1045-74.
19. Hajdu R, Thompson R, Sundelof JG et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK 0991 (L-743, 872) Antimicrob Agents Chemother 1997;41:2339-44.
20. Hoang AT. Caspofungin acetate: an antifungal agent. Am J HealthSyst Pharm 2001;58:1206-14.
21. Jarvis WR, Edwards JR, Culver DH, Hughes JM, Horan T, Emon TG. Nosocomial infection rates in adult and pediatric care units in the United States. National Nosocomial Infections Surveillance. System. Am J Med 1991;91:1855-915.
22. Keating GM and Jarvis B. Caspofungin. Drugs 2001;61:1121-9.
23. Khoo SH, Dening DW. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1994;19:S41-S48.
24. th ICAAC;2000 Sept 18;Toronto.
25. Merck & Co Cancidas (caspofungin acetate) prescribing information, Merck & Co. Available from URL: http://www.merck.com (Accessed 2001 Mar 16).
26. Morrisson VA., Hanke RJ, Weisdorf, DJ. The spectrum of non-candidal infections following bone marrow transplantation. Medecine 1993;72:78-89.
27. Nelson PW, Lozano-Chiu M, Rex JH. In vitro growth-inhibitory activity of pneumocandins L733, 560 and L743, 872 against putatively amphotericinB and fluconazole-resistant Candida isolates: influence of assay conditions. J Med Vet Mycol 1997;35:285-7.
28. Powles MA, Liberator P, Anderson J et al. Efficacy of MK0991 (L743, 872), a semisynthetic pneumocandin in murin models of Pneumocystis carinii. Antimicrob Agents Chemother 1998;42:1985-9.
29. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
30. th ICAAC 1997 Sep 28; Toronto.
31. Sable CA, Nguyen BY, Cholakewitz JA et al. Safety caspofungin acetate (CA) in the treatment of fungal infections (poster). Focus on Fungal Infections 11;2001 Mar 14;Washington DC.
32. th ICAAC;1998 Sept 25; San Diego.
33. th ICAAC; 2000 Sept 18;Toronto.
34. Walsh TJ, Gonzales C, Roilides E et al. Fungemia in children infected with the human immunodeficiency virus: new epidemiologic patterns, emerging pathogens and improved outcome with antifungal therapy. Clin Infect Dis 1995;20:900-6.
35. Wingard JR, White MH, Anaissie E et al. A randomised, doubleblind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-6.